Table 2: Adverse pathologic features in patients who underwent surgery as initial treatment for prostate cancer.
|
Adverse pathologic features |
Clinical risk classification |
|
||
|
LR-PC % (n) |
FIR-GG1 % (n) |
FIR-GG2 % (n) |
p-value |
|
|
Grade Group 3 |
5.1% (2293) |
10% (335) |
14% (3858) |
<.01 |
|
Grade Group 4 or 5 |
0.9% (437) |
2% (88) |
2% (704) |
<.01 |
|
pT3a |
8.4% (4161) |
12.7% (497) |
14.9% (4364) |
<.01 |
|
pT3b |
1.1% (548) |
2.2% (86) |
3.1% (921) |
<.01 |
|
pT4 |
0.05% (27) |
0.12% (5) |
0.05% (14) |
<.01 |
|
Pathologic nodal metastasis |
0.3% (83) |
0.6% (14) |
1% (207) |
<.01 |
|
Positive margin |
19% (9294) |
24% (912) |
20% (5894) |
<.01 |